| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b9ae1ec3a0af1d9c7170af76daee95e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49790ed5b8ddc5fa27a1d47732c612df |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 |
| filingDate |
2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b69288ae0bebb2c7f16f83edc3dc5ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90cd140cbfdb5892961d307eb9a8fb79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_991039797c5090d371fccedeb5711aee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_634e0959ceb0385ac20e140938c1f973
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78041d109a8cbb4a5b160e47e844709d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41db79bf4dc55e911bd944c083b02b55 |
| publicationDate |
2019-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-109207430-A |
| titleOfInvention |
A kind of chimeric antigen receptor NK cell and its preparation method and application |
| abstract |
The invention discloses a chimeric antigen receptor NK cell, a preparation method and application thereof, and relates to the technical field of cellular immunotherapy. The chimeric antigen receptor NK cells disclosed in the present invention can simultaneously express IL-15 and a chimeric antigen receptor targeting CD19, the chimeric antigen receptor NK cells have a good killing effect on tumor cells, and can be used for the preparation of anti-tumor cells. Tumor drugs provide a new idea and method for the treatment of tumors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112301060-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022156786-A1 |
| priorityDate |
2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |